Wallstreet: Major stocks should be included in every portfolio. What exactly do I mean by “beast”? I’m referring to firms with a strong track record of earnings and bright future prospects. They frequently lead their industries.
Table of Contents
These players may be found in other industries, but today I want to concentrate on the healthcare industry. In reality, I’m going to shine a light on one of the world’s leading biotech businesses as well as a significant pharmaceutical company. I will buy shares in these two monstrous stocks without hesitation. Let’s take a look at who these guys are and why you should include them in your portfolio for both the short and long term.
Through its cystic fibrosis (CF) therapies, Vertex Pharmaceuticals (NASDAQ: VRTX) generates billions of dollars a year in revenue. The firm is a global leader in this industry and plans to remain so for the next decade and beyond.
Vertex’s Trikafta can now cure 90% of CF patients, and the firm is developing a medication for the remaining CF population that cannot be addressed by its current therapies. Vertex is also testing another drug in pivotal trials who might surpass Trikafta. As a result, you may put your faith in the CF portfolio.
Additionally, Vertex has achieved revenue growth, positive cash flow, and returns on invested capital over time.
Vertex is pushing into additional therapeutic areas to increase investment potential, and the progress thus far appears encouraging. The business has entered into a binding agreement to purchase CRISPR Therapeutics, a company that specializes on one-time therapeutic treatments for blood diseases, with a signal expected by the end of the year and a decision expected in March. Vertex is also developing candidates for high-demand fields including as pain treatment and Type 1 diabetes.
Vertex’s shares are still inexpensive, despite a 21% gain in the first half of this year. They are selling at only 24 times the future earnings projection, a price at which I would gladly invest in a firm that is still in its early stages and has outstanding long-term potential.
Johnson & Johnson (NSE: JNJ) is a global pharmaceutical conglomerate. You may recognize them from goods such as Band-Aids and Tylenol. However, J&J is separating that company into a new organization dubbed “Consumer Health.”
But don’t worry, J&J is making a terrific move. This is because J&J’s two major business areas, Pharmaceuticals and Medical Devices, produce greater revenue and growth. As a result of the split, they will be able to use their resources more efficiently for these firms. It should also allow J&J to achieve significant revenue growth.
J&J has set a target of $60 billion in revenue from its Pharmaceutical sector by 2025, up from $52 billion last year. Furthermore, there is room for expansion in the MedTech industry. J&J’s MedTech business now has a dozen platforms with annual sales surpassing $1 billion, thanks to the acquisition of Abiomed, a heart pump startup, last year.
You’ll also like J&J for its dividends and diverse growth. The corporation is known as a dividend king, having distributed dividends for at least 50 years. This demonstrates J&J’s dedication to sharing success with shareholders, and we can anticipate that this will continue. J&J has the wherewithal to maintain its growth trajectory, with $16 billion in free cash flow.
Today, J&J trades at almost 15 times projected profits, a figure that is lower than the 18 times it traded at around a year ago. When we examine J&J’s track record and its emphasis on the possible new age of development as it devotes its attention to its two main divisions, this is a tempting entry opportunity.